April 17, 2024
Apr 16, 2024 – Press Release: Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS
- /
- /
Media / Press Releases Tuesday, Apr 16, 2024 Results from the Phase III study showed that subcutaneous (SC) injection was consistent with…